Labcorp Launches First FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

Abbott Laboratories reported a 13% year-on-year revenue increase in the second quarter of 2026, with like-for-like sales up 4.8%, and announced a quarterly dividend of $0.63 per share, an annualized payout of $2.52. The company has raised its dividend for 54 consecutive years, though its annualized payout ratio of about 82% of trailing earnings of $3.09 per share sits on the high side, while its free-cash-flow payout ratio is roughly 56% on about $9.9 billion in operating cash flow and $7.8 billion in free cash flow over the past 12 months. Abbott's acquisition of Exact Sciences has expanded its cancer diagnostics business, and it recently obtained a CE Mark for Libre Duo, a sensor tracking both glucose and ketone levels. In the first half of 2026, reported sales rose 10.5% while comparable sales rose 4.3%, and trailing-12-month revenue has reached around $46.6 billion. The stock trades at about 33.5 times trailing earnings and 17 times forward earnings, with a dividend yield of about 2.5%.

Kaipu Biotech announced that its wholly owned subsidiary, Chaozhou Kaipu Biochemical Co., Ltd., has obtained a medical device registration certificate issued by the National Medical Products Administration. The approved product is a vaginal microbial nucleic acid detection kit, using PCR-fluorescent probe method, classified as a Class III in vitro diagnostic reagent. The product is used for qualitative detection of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans nucleic acids in vaginal secretions.

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.

GE HealthCare announced a definitive agreement on October 5 to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. The deal builds on an exclusive licensing agreement struck in October 2023 covering development and commercialization of Fluorine-18 FAPI-74 outside the United States and global rights to Gallium-68 FAPI-46, and it would add U.S. rights to F-18 FAPI-74 while expanding GE HealthCare's domestic radiopharmaceutical manufacturing network. The company also recently received CE Mark approval for its Photonova Spectra photon-counting CT scanner, its third clearance across key geographies in five months. In the second quarter of fiscal 2026, adjusted EBIT margin fell 40 basis points year over year to 14.2%, though diluted EPS rose 16.5%, a figure that included a one-time $129 million tariff refund under the International Emergency Economic Powers Act. After $2.3 billion of strategic acquisitions in the first half, GE HealthCare reported $10.1 billion in total debt and $2.1 billion in cash and equivalents at quarter-end.